Pomegra
Johnson & Johnson (JNJ) shares slipped after a $5.5B talc settlement charge cut Q3 profit 96%, though sales and adjusted EPS beat and 2026 guidance rose.
- Q3 GAAP net income fell 95.9% to $210M on a $5.5B pre-tax talc charge; GAAP EPS was $0.09.
- Sales rose 5.9% to $25.4B and adjusted EPS of $2.59 beat consensus of roughly $2.54.
- 2026 adjusted EPS guidance rose to $11.05-$11.15; JNJ fell about 2.5% premarket.
Lead
Johnson & Johnson (NYSE: JNJ) reported third-quarter results on October 13 in which a one-time litigation charge overshadowed an operating beat. The company booked a pre-tax charge of about $5.52B for its proposed resolution of ovarian talc litigation. Reported net income fell to $210M from roughly $5B a year earlier, a decline of about 96%. Revenue and adjusted earnings still topped expectations, and management raised its full-year outlook.What Happened in J&J's Third Quarter?
Worldwide sales rose 5.9% to $25.4B, or 6.0% on an operational basis, ahead of the roughly $25.3B consensus. Adjusted diluted EPS was $2.59, down 7.5% from $2.80 a year earlier but above the $2.54 estimate. Adjusted net income fell 6.8% to $6.34B.
The gap between reported and adjusted results reflects special items. Beyond the talc charge, the quarter absorbed about $1B of in-process R&D expense tied to the acquisition of Firefly Bio, plus costs from a strategic collaboration with Sail Biomedicines. Together these pushed GAAP EPS down 95.8% to $0.09.
Innovative Medicine sales rose 7.7% to $16.76B. Growth came from Tremfya, which rose to about $2.4B from $1.4B, along with the cancer drugs Darzalex and Carvykti and the neuropsychiatry products Spravato and Caplyta. Stelara, which faces biosimilar competition, fell to about $0.7B from $1.6B and cost the segment roughly 6.9 percentage points of growth. MedTech sales rose 2.5% to $8.64B. International device sales were flat, held back by geopolitical headwinds.What Is in the Talc Settlement?
The talc settlement is a $5.5B commitment to resolve ovarian cancer claims through per-claim payments. J&J disclosed the agreement in July, and the third-quarter charge reflects it in full. It covers roughly 76,000 remaining ovarian claims. The first payment, capped at $3B, falls due in 2027, and no further payments are due before 2028.
The schedule means the cash cost lands after the accounting hit. The charge cuts 2026 reported earnings, while 2026 operating cash flow is largely unaffected.
Why Did J&J Shares Fall Despite the Beat?
J&J shares fell because the headline profit decline and softer underlying trends outweighed the beat. The stock slipped about 2.5% in premarket trading and was already below its 20-day and 50-day moving averages heading into the report.
Three factors weighed on sentiment. Adjusted EPS fell year over year for the quarter. MedTech growth of 2.5% lagged the pharmaceutical business by more than five points. Margins were pressured by Stelara erosion and acquisition-related spending. Estimate revisions into the print also leaned negative, with a dozen downward revisions over the prior 90 days and none upward.
What Did J&J Raise in Its 2026 Outlook?
J&J raised its 2026 adjusted EPS guidance by $0.06 to a range of $11.05-$11.15, a midpoint of $11.10 and growth of about 2.9%. That sits slightly above the roughly $11.08 consensus. Adjusted operational EPS is now expected at $10.95-$11.05, growth of about 2%.
Sales guidance moved to $101.0B-$101.4B, a midpoint of about $101.2B and growth of 7.4%. The range brackets the $101.3B consensus, so the revenue raise was largely in line with expectations. The pharmaceutical franchise carries most of that growth, while device sales are expected to remain the slower contributor.
Strategic Context
The quarter shows the company pursuing two goals at once: closing its largest legacy liability and reinvesting in oncology and immunology. The talc deal removes a long-running overhang that had delayed earlier resolution attempts through bankruptcy court. The Firefly Bio and Sail Biomedicines transactions add early-stage pipeline assets, at the cost of near-term GAAP earnings.
Outlook
J&J enters the fourth quarter with its largest litigation exposure priced and scheduled, and a pharmaceutical business growing near 8% even as Stelara declines. Remaining questions are whether MedTech can accelerate from 2.5% and whether Tremfya, Darzalex and Carvykti can keep offsetting biosimilar erosion. The first talc payment of up to $3B in 2027 is the next defined cash milestone.
